Abstract
Matrix metalloproteinases (MMP) have been implicated in several steps of tumor metastasis, such as invasion in the extracellular matrix, intravasation, extravasation, and growth in a distant organ site. Various synthetic MMP inhibitors have been reported to suppress tumor metastasis in animal models. However, there are few reports describing which steps in the metastasis process are most critical for inhibition by MMP inhibitors. In the experimental lung colonization model by i.v. injection of mouse B16-F10 melanoma cells, we found that the daily administration of MMI270 for 2 weeks significantly decreased the number of colonies in the lung compared with the control without affecting the size of colony. Micrometastasis was monitored day 7 post-inoculation by measuring the melanin content in the lung as well as by microscopic examination of the lung tissue sections. Even only twice administrations of MMI270 on the first day after tumor injection significantly inhibited micrometastasis in the lung. In the spontaneous metastasis model using B16-BL6 melanoma cells, lung metastasis was not affected by a continuous administration of MMI270 using a mini osmotic-pump. On the contrary, when mice were subjected to popliteal lymphadenectomy on day 7 after the cell inoculation in the footpad subdermis, the continuous administration of MMI270 significantly suppressed the lung metastasis. These results suggest that the tumor cell extravasation in the target organ is the most critical step where MMPs can play their significant role in the experimental metastasis, and that the lymphatic metastasis process is less susceptible to MMI270 than the hematogenic metastasis process in the spontaneous metastasis model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MMP:
-
Matrix metalloproteinase
- TIMP:
-
Tissue inhibitor of metalloproteinase
- MMP-2:
-
72-kDa gelatinase A
- MMP-9:
-
92-kDa gelatinase B
- MT1-MMP:
-
Membrane-type 1 matrix metalloproteinase
References
McCawley LJ, Matrisian LM (2000) Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6:149–156. doi:10.1016/S1357-4310(00)01686-5
Nagase H, Woessner JF (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494. doi:10.1074/jbc.274.31.21491
Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis a moving target for therapeutic intervention. J Clin Invest 103:1237–1241. doi:10.1172/JCI6870
Gomez DE, Alonso DF, Yoshiji H et al (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111–122
Wojtowicz-Praga SM, Dickson RB, Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Invest New Drugs 15:61–75. doi:10.1023/A:1005722729132
Curran S, Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189:300–308. doi :10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C
Fridman R, Toth M, Pena D et al (1995) Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 55:2548–2555
Stetler-Stevenson WG, Aznavoorian S, Liotta LA (1993) Tumor cell interactions with extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 9:541–573. doi:10.1146/annurev.cb.09.110193.002545
Sato H, Takino T, Okada Y et al (1994) A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370:61–65. doi:10.1038/370061a0
Gilles C, Polette M, Piette J et al (1996) High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 65:209–213. doi :10.1002/(SICI)1097-0215(19960117)65:2<209::AID-IJC14>3.0.CO;2-8
Nomura H, Sato H, Seiki M et al (1995) Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55:3263–3266
Brown PD (1995) Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35:293–301. doi:10.1016/0065-2571(94)00022-U
Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–193. doi:10.1093/jnci/93.3.178
Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75:69–75. doi:10.1016/S0163-7258(97)00023-5
Talbot DC, Brown PD (1996) Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A:2528–2533. doi:10.1016/S0959-8049(96)00398-X
Eccles SA, Box GM, Court WJ et al (1996) Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res 56:2815–2822
Chirivi RG, Garofalo A, Crimmin MJ et al (1994) Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer Res 58(3):460–464. doi:10.1002/ijc.2910580326
Nakamura ES, Koizumi K, Yamaura T et al (2003) Anti-tumor angiogenic effect of a metalloproteinase inhibitor MMI270. Anticancer Res 23(1A):411–417
Naglich JG, June-Kunkel M, Gupta E et al (2001) Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 61:8480–8485
Watts KP, Fairchild RG, Slatkin DN et al (1981) Melanin content of hamster tissues, human tissues, and various melanomas. Cancer Res 41:467–472
Levitt NC, Eskens FA, O’Byrne KJ et al (2001) Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7:1912–1922
Kurschat P, Zigrino P, Nischt R et al (1999) Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 274:21056–21062. doi:10.1074/jbc.274.30.21056
Hofmann UB, Westphal JR, Van Muijen GN et al (2000) Matrix metalloproteinases in human melanoma. J Invest Dermatol 115:337–344. doi:10.1046/j.1523-1747.2000.00068.x
Heyder C, Gloria-Maercker E, Entschladen F et al (2002) Realtime visualization of tumor cell/endothelial cell interactions during transmigration across the endothelial barrier. J Cancer Res Clin Oncol 128:533–538. doi:10.1007/s00432-002-0377-7
Karpanen T, Alitalo K (2008) Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol Mech Dis 3:367–397. doi:10.1146/annurev.pathmechdis.3.121806.151515
Elias EG, Didolkar MS, Goel IP et al (1977) A clinicopathologic study of prognostic factors in cutaneous malignant melanoma. Surg Gynecol Obstet 144:327–334
Meier F, Will S, Ellwanger U et al (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147:62–70. doi:10.1046/j.1365-2133.2002.04867.x
Hofmann UB, Eggert AA, Blass K et al (2003) Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res 63:8221–8225
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kasaoka, T., Nishiyama, H., Okada, M. et al. Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. Clin Exp Metastasis 25, 827–834 (2008). https://doi.org/10.1007/s10585-008-9198-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-008-9198-7